COST-EFFECTIVENESS OF MULTIPLEXED PREDICTIVE BIOMARKER SCREENING IN NON-SMALL CELL LUNG CANCER

被引：0
|
作者：
Romanus, D. [1 ]
Cardarella, S. [2 ]
Cutler, D. [1 ]
Landrum, M. B. [1 ]
Lindeman, N. [3 ]
Gazelle, G. S. [4 ]
机构：
[1] Harvard Univ, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Boston, MA 02115 USA
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 03期
关键词：
D O I：
10.1016/j.jval.2015.03.1184
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN87
引用
收藏
页码：A204 / A204
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness of Multiplexed Predictive Biomarker Screening in Non-Small-Cell Lung Cancer
    Romanus, Dorothy
    Cardarella, Stephanie
    Cutler, David
    Landrum, Mary Beth
    Lindeman, Neal I.
    Gazelle, G. Scott
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (04) : 586 - 594
  • [2] Cost-effectiveness of diagnostic interventions. Non-small cell lung cancer
    Langer, A.
    [J]. ONKOLOGE, 2010, 16 (10): : 992 - +
  • [3] Cost-effectiveness of smoking cessation in patients with non-small cell lung cancer
    Kunde, Katharina
    [J]. GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2023, 28 (04): : 150 - 151
  • [4] Cost-effectiveness evaluation of low-dose computed tomography screening for non-small cell lung cancer
    Wisnivesky, JP
    Braz-Parente, D
    Smith, JP
    Yankelevitz, DF
    Henschke, CI
    [J]. RADIOLOGY, 2000, 217 : 244 - 244
  • [5] Cost-Effectiveness of Hybrid PET/CT for Staging of Non-Small Cell Lung Cancer
    Schreyoegg, Jonas
    Weller, Julia
    Stargardt, Tom
    Herrmann, Ken
    Bluemel, Christina
    Dechow, Tobias
    Glatting, Gerhard
    Krause, Bernd J.
    Mottaghy, Felix
    Reske, Sven N.
    Buck, Andreas K.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (11): : 1668 - 1675
  • [6] Cost-effectiveness of mediastinal lymph node staging in non-small cell lung cancer
    Czarnecka-Kujawa, Katarzyna
    Rochau, Ursula
    Siebert, Uwe
    Atenafu, Eshetu
    Darling, Gail
    Waddell, Thomas Kenneth
    Pierre, Andrew
    De Perrot, Marc
    Cypel, Marcelo
    Keshavjee, Shaf
    Yasufuku, Kazuhiro
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2017, 153 (06): : 1567 - 1576
  • [7] A REVIEW OF COST-EFFECTIVENESS STUDIES OF PEMBROLIZUMAB FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER
    Qiao, N.
    Insinga, R.
    Burke, T.
    Lopes, G.
    [J]. VALUE IN HEALTH, 2020, 23 : S41 - S42
  • [8] Comparing the cost-effectiveness of perioperative immunotherapy strategies in non-small cell lung cancer
    Muthusamy, B.
    Zabor, E. C.
    Pennell, N. A.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S743 - S743
  • [9] Cost-effectiveness of pemetrexed for previously treated advanced non-small cell lung cancer
    Pavlakis, N
    Mitchell, PL
    Slynes, G
    Aristides, M
    Davey, P
    Rajan, N
    Arora, B
    Liepa, AM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 549S - 549S
  • [10] Evaluation of Cost-effectiveness of FDG-PET in Non-Small Cell Lung Cancer
    Hoekstra, Otto S.
    van Tinteren, Harm
    Smit, Egbert F.
    [J]. PET CLINICS, 2006, 1 (04) : 329 - +
12345